FIG 5.

Clinical performance of tumor- and immune-related risk parameters and predictive value. (A) Cox multivariable regression analysis of overall survival combining the three-category Immunoscore: low (Lo, 0%-25%), Intermediate (Int, > 25%-70%), and high (Hi, > 70%-100%) with clinical parameters: sex, T stage, N stage, sidedness, and microsatellite instability (MSI) status. (B) Relative importance of each risk parameter to survival risk for overall survival using the χ² proportion test for clinical parameters and Immunoscore. Significant prediction of survival using likelihood ratio test. Forest plots representing the predictive value of response to chemotherapy (time to recurrence [TTR]) in (C) Immunoscore groups: I0 (0%-10%), I0-1, I1(> 10%-25%), I1-2, I2 (> 25%-70%), I2-3, I3, (> 70%-95%), and I3-4( > 95%-100%), (D) Immunoscore Lo and Int + Hi, and (D) among high-risk (T4 or N2) and (E) low-risk (T1-T3 and N1) patient subgroups. (*) Subgroup analysis for postoperative chemotherapy with No Chemotherapy as reference. (**): Significant multivariable Wald P value < .01. CoxPH, Cox proportional hazards test P value; HR, hazard ratio, MSS, microsatellite stable.